Advertisement

Search Results

Advertisement



Your search for what matches 6155 pages

Showing 101 - 150


solid tumors
issues in oncology
immunotherapy

Parker Institute for Cancer Immunotherapy Names New CEO

The Parker Institute for Cancer Immunotherapy announced the appointment of Karen E. Knudsen, MBA, PhD, as the new Chief Executive Officer (CEO) of the institute. A visionary leader in oncology, health-care delivery, scientific innovation, and strategic transformation, Dr. Knudsen will take on her...

integrative oncology

Building and Sharing Dietary Evidence in Cancer Care

Guest Editor’s Note: Several epidemiologic studies have shown an inverse association between healthy dietary patterns and the risk of chronic diseases including cancer. Patients are often interested in exploring different dietary interventions throughout the cancer continuum. However, concrete...

Case 3: Progression of HR-Positive/HER2-Negative Metastatic Breast Cancer After Adjuvant CDK4/6 Inhibition

This is Part 3 of PI3K Inhibition Strategies for HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Adam Brufsky, Heather McArthur, and Seth Wander discuss the treatment of...

breast cancer

Case 1: First-Line Therapy in HR-Positive Metastatic Breast Cancer

This is Part 1 of PI3K Inhibition Strategies for HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Adam Brufsky, Heather McArthur, and Seth Wander discuss the first-line...

bladder cancer

TB Vaccination Could Enhance BCG Response in Patients With Non–Muscle-Invasive Bladder Cancer, Study Finds

Two doses of a simple tuberculosis (TB) vaccination after surgery helps the immune system fight cancer cells and may improve patient outcomes among those with non–muscle-invasive bladder cancer, according to a pilot study of 40 patients. Initial results from the RUTIVAC-1 Trial were presented by...

breast cancer

Conundrums in Treating HER2-Positive Early Breast Cancer

Today’s oncologists are blessed with an abundance of therapies for HER2-positive early breast cancer, but this comes with the challenge of selecting among them. At the 2025 Miami Breast Cancer Conference, Sara A. Hurvitz, MD, FACP, offered insight on common clinical scenarios. Dr. Hurvitz is...

breast cancer

Results Announced From Phase II VERITAC-2 Clinical Trial in Breast Cancer

Arvinas, Inc. and Pfizer Inc. recently announced results from the randomized phase III VERITAC-2 clinical trial (ClinicalTrials.gov identifier NCT05654623) evaluating vepdegestrant monotherapy vs fulvestrant in adults with estrogen receptor–positive, HER2-negative advanced or metastatic breast...

palliative care

Bringing Palliative Care to Every Patient With Cancer

Janet L. Abrahm, MD, FACP, FAAHPM, FASCO, has spent more than half of her oncology career as a palliative care physician. After receiving her medical degree from the University of California, San Francisco (UCSF), in 1973, Dr. Abrahm completed her internship and residency at Massachusetts General...

global cancer care
issues in oncology

Confronting the Growing Global Threat of Antimicrobial Resistance in Cancer Care

The dire warnings about the lethal consequences of unchecked antimicrobial resistance are getting louder and becoming more urgent. The U.S. Department of Health and Human Services has called antimicrobial resistance “one of the most important health security threats of our time,” with at least 2.8...

issues in oncology
solid tumors

New Guideline Supports Transoral Robotic Surgery in the Multidisciplinary Management of Patients With Oropharyngeal Cancer

Transoral robotic surgery (TORS) can offer patients with oropharyngeal squamous cell carcinoma (OPSCC) improved survival while minimizing or avoiding late toxicities associated with the standard of care of radiation with cisplatin chemotherapy, according to a recent ASCO guideline.1 “We show in a...

lymphoma

inMIND Trial: Tafasitamab Plus Lenalidomide and Rituximab in Relapsed or Refractory Follicular Lymphoma

The addition of tafasitamab, a CD19 monoclonal antibody, to the commonly used lenalidomide and rituximab backbone significantly improved progression-free survival in patients with relapsed or refractory follicular lymphoma, according to data presented during the 2024 American Society of Hematology...

gastroesophageal cancer

Neoadjuvant Chemoradiotherapy Plus Immunotherapy in Esophageal Squamous Cell Carcinoma

Neoadjuvant therapy that combines chemotherapy, radiotherapy, and the investigational PD-1 inhibitor sintilimab led to a significantly higher pathologic complete response rate in patients with locally advanced esophageal squamous cell carcinoma, according to data presented at the 2025 ASCO...

solid tumors

Intraperitoneal Paclitaxel Combination Regimen Improves Overall Survival in Advanced Gastric Cancer

Adding intraperitoneal (IP) paclitaxel to standard intravenous (IV) paclitaxel plus S-1 (oral fluoropyrimidine derivative) significantly extended overall survival for patients with gastric cancer peritoneal metastases, according to data presented at the 2025 ASCO Gastrointestinal Cancers...

breast cancer

Is Active Monitoring a Safe Option for Patients With Ductal Carcinoma In Situ?

With right-sizing treatment an aim of many treatment approaches in breast cancer today, ductal carcinoma in situ (DCIS), as well as its overtreatment, has become a potential target of change. Which patients, however, might safely forgo the current recommendations and be safely followed with active...

breast cancer

Case 1: De Novo Metastatic HR-Positive/HER2-Positive Breast Cancer

This is Part 1 of Evolving Paradigms in the Treatment of HR-Positive/HER2-Positive Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable.    In this video, Drs. Sara Tolaney, Ian Krop, and Mark Pegram discuss the treatment of de...

lung cancer

MRD and Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA NSCLC

The ADAURA trial findings showed a significant benefit in disease-free survival with the EGFR inhibitor osimertinib, compared to placebo, making it the recommended standard of adjuvant treatment in patients with EGFR-mutated non–small cell lung cancer (NSCLC) for up to 3 years after surgery. In a...

kidney cancer

Nivolumab Plus Cabozantinib Continues to Show Superior Long-Term Outcomes in Advanced Renal Cell Carcinoma

The PD-1 inhibitor nivolumab plus the tyrosine kinase inhibitor cabozantinib continues to demonstrate a significant survival advantage over sunitinib alone in patients with previously untreated advanced renal cell carcinoma, according to data presented at the 2025 ASCO Genitourinary Cancers...

issues in oncology

Two Decades of Collaboration: The Accelerating Anticancer Agent Development and Validation (AAADV) Workshop

Over the past 20 years, the investment in research and development of cancer therapies has been unprecedented, and the pace of new drug development has been accelerating. To illustrate this trajectory, the U.S. Food and Drug Administration (FDA) approved 71 treatments for solid cancers in adults...

integrative oncology

Digital Integrative Medicine Intervention for Patients Undergoing Active Cancer Treatment

Cancer and its treatments often contribute to burdensome symptoms that negatively impact patients’ quality of life and treatment outcomes, including fatigue, anxiety, and depression.1 Many patients experience multiple symptoms concurrently2 that can disrupt their treatments and lead to unplanned...

issues in oncology
global cancer care
health-care policy

How the Cancer Moonshot Is Making a Difference for Patients Here and Across the World

Catharine Young, PhD, has spent the past decade of her career focused on cancer policy and advocacy. A native of Johannesburg, South Africa, Dr. Young served as Senior Director of Science Policy at the Biden Cancer Initiative, which began in 2017 by then former Vice President Joe Biden. There she...

solid tumors
breast cancer
issues in oncology
cardio-oncology
supportive care
symptom management

SGLT2 Inhibitors Could Help Protect Against Heart Failure in Patients With Cancer

A common type of diabetes drug known as sodium-glucose cotransporter-2 (SGLT2) inhibitors could help patients with cancer achieve greater long-term recovery, according to a novel study published by Bhalraam et al in the European Journal of Preventive Cardiology. Background Many patients with cancer ...

skin cancer
lymphoma
issues in oncology

Is There a Link Between Tattoos and Increased Cancer Risk?

Skin cancers and lymphoma may be more prevalent among individuals with tattoos compared with those without tattoos, according to a recent study published by Clemmensen et al in BMC Public Health. Prior research has shown that tattoo ink does not just remain at the site of injection—instead, when...

Francis S. Collins, MD, PhD, Retires From the National Institutes of Health

Francis S. Collins, MD, PhD, announced in a statement his retirement as Director of the National Institutes of Health (NIH), effective February 28, 2025. Dr. Collins is the longest-serving presidentially appointed NIH Director, having served three U.S. presidents over more than 12 years—Barack...

gastrointestinal cancer
issues in oncology

Bacterial Leakage Across Gastric Lining Could Signify Cancer Risk

Researchers may have uncovered insights into the role of bacteria in the development of gastric cancer, according to a novel study published by Giddings et al in Helicobacter. The findings could pave the way for a more effective precancer treatment option. Background  Gastric cancer is the fourth...

supportive care
immunotherapy
symptom management
issues in oncology

Text Message Platform May to Help Address ‘Time Toxicity’ in Patients With Cancer

Digital technology may help to safely reduce the amount of time some patients with cancer spend receiving care—also referred to as “time toxicity”—according to a recent study published by Bange et al in NEJM Catalyst. Background Patients with cancer often spend a large amount of time on activities...

issues in oncology
supportive care
geriatric oncology

Cancer, Aging, and Meaning: Navigating Psychosocial Challenges

I’ve learned a lot about medicine over the years, but one thing I wasn’t taught was how to guide someone through the existential weight of dying. My education centered on diagnosing, curing, or at least managing disease—not on the delicate art of helping people and their loved ones cope with what...

gynecologic cancers
immunotherapy
issues in oncology

Flagellin and Immune Checkpoint Inhibition in Patients With Ovarian Cancer

The interference of gut bacteria could explain the ineffectiveness of immune checkpoint therapy in some patients with ovarian cancer, according to a recent study published by McGinty et al in Cancer Immunology Research.  Background There are over 10,000 ovarian cancer–related deaths in the United...

breast cancer

I’m a 2.0 Version of Myself After Cancer

Although there’s no history of breast cancer in my family, when I was 10, my pediatrician introduced me to breast self-exams, so I would become familiar with my breasts and learn to spot any unusual changes as I got older. I remember her telling me this was an especially important exercise to do...

palliative care
lung cancer

How Telehealth Is Broadening Access to Early Palliative Care and Improving Outcomes for Patients With Advanced Lung Cancer

Although national guidelines, including ASCO’s palliative care guideline,1 call for the early integration of palliative and oncology care for patients with advanced cancer, only 36% of those with a very poor prognosis and 18% of those with a poor prognosis receive palliative care services.2 The...

issues in oncology
solid tumors

Only Half of Young Adults With Cancer Are Told of Fertility Preservation Options by Their Providers: Strategies for Improving That Number

Each year in the United States, approximately 90,000 adolescents and young adults (AYAs), defined as those between the ages of 15 and 39, are diagnosed with cancer, and about 9,300 die of the disease.1 Worldwide, the number of new cases of cancer in this age population tops 1,300,200—an increase of ...

colorectal cancer

Dual Immunotherapy Extended Progression-Free Survival in Metastatic Colorectal Cancer Subgroup

An immunotherapy combination for advanced, highly mutated colorectal cancer has significantly delayed disease progression vs single-agent therapy, according to data presented at the 2025 ASCO Gastrointestinal Cancers Symposium.1 The phase III CheckMate 8HW trial compared the PD-1 inhibitor...

multiple myeloma
myelodysplastic syndromes
leukemia

In Case You Missed It: Additional Studies of Interest From ASH 2024

A record-breaking number of abstracts were submitted for the 2024 American Society of Hematology (ASH) Annual Meeting & Exposition, and nearly 8,000 were accepted. The ASCO Post strives to provide in-depth coverage of those with the greatest impact. Here, we offer snapshots of others of...

leukemia

Novel Menin Inhibitors Show Safety and Activity in Several Clinical Trials

The recently approved menin inhibitor revumenib is poised to improve the treatment of acute myeloid leukemia (AML), specifically for disease with a KMT2A rearrangement. Promising results for other novel menin inhibitors now in development—with their unique safety and activity profiles—suggest the...

leukemia

Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL

A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL), including those with isolated or combined extramedullary...

myelodysplastic syndromes

BOREAS Trial: Navtemadlin Demonstrates Clinical Benefit in JAK Inhibitor–Refractory Myelofibrosis

The oral MDM2 inhibitor navtemadlin is the first single agent to demonstrate significant efficacy in JAK (Janus kinase) inhibitor–refractory myelofibrosis, achieving improvements in spleen volume, symptoms, and biomarkers, according to data presented at the 2024 American Society of Hematology (ASH) ...

colorectal cancer

New Findings on Aspirin and Risk of Colorectal Cancer Recurrence

According to one of the first biomarker-driven randomized study in people with nonmetastatic colorectal cancer, taking 160 mg of aspirin daily after treatment ends may reduce the risk of cancer recurrence in patients with cancers that harbor a PI3K mutation. These mutations are common to many types ...

lung cancer

Getting a Lung Cancer Diagnosis Was Shocking

For more than a year before my diagnosis of stage IA non–small cell lung cancer (NSCLC), in 2020, I had been self-treating a relentless chronic cough and a slight feeling of tightness in my chest. The symptoms were similar to asthma, so I began using albuterol inhalers. When they stopped working, I ...

multiple myeloma

AQUILA Trial: Daratumumab Proves Beneficial in Smoldering Multiple Myeloma

Patients with smoldering multiple myeloma derived a significant progression-free survival benefit, along with other positive outcomes, from 3 years of subcutaneous use of the monoclonal antibody daratumumab as compared with active monitoring in the phase III AQUILA study.1 These findings were...

breast cancer

Imlunestrant Alone or With Abemaciclib: An All-Oral Targeted Therapy for ER-Positive Advanced Breast Cancer

The investigational next-generation oral selective estrogen receptor degrader (SERD) imlunestrant improved progression-free survival both as monotherapy in patients with ESR1 mutations and in combination with the CDK4/6 inhibitor abemaciclib regardless of ESR1 mutational status in patients with...

breast cancer
survivorship
supportive care
symptom management
issues in oncology

Telephone-Based Therapy May Reduce Fatigue Interference With Functioning in Metastatic Breast Cancer Survivors

Telephone-delivered acceptance and commitment therapy may be effective in reducing the interference of fatigue with functioning and improving the quality of life among survivors of metastatic breast cancer, according to a recent study published by Mosher et al in the Journal of Clinical Oncology....

solid tumors
issues in oncology

PFAS Contamination in Drinking Water May Be Linked to Several Rare Cancers

Investigators may have uncovered an association between manufactured per- and polyfluoroalkyl substances (PFAS) levels in drinking water and the incidence of certain digestive, endocrine, lung, oral, and pharyngeal cancers, according to a novel study published by Li et al in the Journal of Exposure ...

cns cancers
genomics/genetics
issues in oncology

New Study Identifies Genes That Could Be Implicated in Glioblastoma in Adulthood

Researchers have discovered of a new type of stem cell in the brain that could lead to the development of more effective treatments in adult patients with glioblastoma, according to a recent study published by Wang et al in Nature. The finding could help explain how adult brain cells take advantage ...

supportive care
symptom management
solid tumors
issues in oncology

Psilocybin-Based Therapy May Address Mental Health Issues in Patients With Cancer, Addiction

Treatment with psilocybin may improve mental health issues among patients with cancer when accompanied by psychotherapy and could result in lasting, positive personality changes in patients with alcohol use disorder, according to two recent studies published by Petridis et al in Nature Mental...

breast cancer

New Research Approaches to Metastatic Breast Cancer

Tumor cells circulating in the blood are the germ cells of breast cancer metastases. They are rare and could not be propagated in the culture dish until now. A team from the German Cancer Research Center (DKFZ), the Heidelberg Stem Cell Institute HI-STEM, and the NCT Heidelberg has now succeeded...

kidney cancer

Nuclear Speckle Signatures in Clear Cell RCC

Researchers have found a possible source of the variability in patterns of clear cell renal cell carcinoma (RCC), the most common kidney cancer diagnosed in adults. Katherine Alexander, PhD, Assistant Professor at Cold Spring Harbor Laboratory, and Shelley Berger, PhD, Professor at the University...

skin cancer

Allison Betof Warner, MD, PhD, on TIL Therapy for Advanced Melanoma: Innovative Clinical Advances in Treatment

Allison Betof Warner, MD, PhD, reviews important clinical research in the treatment of advanced melanoma, including tumor-infiltrating lymphocyte (TIL) therapy, the role of this innovative treatment in advanced melanoma, and relevant data, peer-reviewed literature, and FDA approvals in 2024. She...

geriatric oncology
issues in oncology
solid tumors

Influence of Social Networks Among Older Patients With Cancer

Researchers have received a $3.5 million grant from the National Cancer Institute to examine the impact of social networks on the decision-making process among older patients with cancer. Background Many individuals have social networks, which includes those who offer a connection and have similar...

breast cancer

Anthracyclines Plus Taxane-Based Chemotherapy for Certain Patients at High Risk for Breast Cancer Recurrence

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2-negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline plus taxane-based chemotherapy regimens compared with those...

supportive care
pain management

Balancing Pain Management and Addiction Risks in Oncology

Managing cancer pain in patients with substance use disorder presents a unique challenge for oncologists, requiring a balance between effective symptom management and mitigation of the risks of substance misuse. During the 2024 JADPRO Live, Antonia Corrigan, MSN, ANP-C, ACHPN, emphasized the...

leukemia
issues in oncology

Combination of Two Oral Agents May Improve Progression-Free Survival in Patients With Previously Untreated CLL

A combination of the oral drugs acalabrutinib and venetoclax may be more effective at improving progression-free survival and minimizing serious adverse events in patients with previously untreated chronic lymphocytic leukemia (CLL) compared with one of two standard multidrug treatment regimens,...

Advertisement

Advertisement




Advertisement